JP2013509431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013509431A5 JP2013509431A5 JP2012537086A JP2012537086A JP2013509431A5 JP 2013509431 A5 JP2013509431 A5 JP 2013509431A5 JP 2012537086 A JP2012537086 A JP 2012537086A JP 2012537086 A JP2012537086 A JP 2012537086A JP 2013509431 A5 JP2013509431 A5 JP 2013509431A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently
- substituted
- cycloalkyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 26
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 12
- 229910052731 fluorine Inorganic materials 0.000 claims 11
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 11
- 125000002947 alkylene group Chemical group 0.000 claims 10
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 125000004429 atom Chemical group 0.000 claims 8
- 229910052801 chlorine Inorganic materials 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 125000005842 heteroatom Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 5
- -1 hydroxypyrrolidinyl Chemical group 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000003003 spiro group Chemical group 0.000 claims 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 2
- 125000000068 chlorophenyl group Chemical group 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000004965 chloroalkyl group Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25599909P | 2009-10-29 | 2009-10-29 | |
| US61/255,999 | 2009-10-29 | ||
| PCT/US2010/054594 WO2011059784A1 (en) | 2009-10-29 | 2010-10-29 | Tricyclic heterocyclic compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013509431A JP2013509431A (ja) | 2013-03-14 |
| JP2013509431A5 true JP2013509431A5 (https=) | 2013-11-21 |
| JP5728487B2 JP5728487B2 (ja) | 2015-06-03 |
Family
ID=43128322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012537086A Expired - Fee Related JP5728487B2 (ja) | 2009-10-29 | 2010-10-29 | 三環式ヘテロ環化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9216972B2 (https=) |
| EP (3) | EP2592071B1 (https=) |
| JP (1) | JP5728487B2 (https=) |
| KR (1) | KR20130036171A (https=) |
| CN (1) | CN102686571B (https=) |
| AU (1) | AU2010319879A1 (https=) |
| ES (1) | ES2759949T3 (https=) |
| MX (1) | MX336881B (https=) |
| WO (1) | WO2011059784A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| HRP20160890T1 (hr) | 2008-08-27 | 2016-09-23 | Arena Pharmaceuticals, Inc. | Derivati supstituirane tricikličke kiseline kao agonisti s1p1-receptora korisni u liječenju autoimunih i upalnih poremećaja |
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| CN105503882B (zh) | 2010-03-03 | 2019-07-05 | 艾尼纳制药公司 | 制备s1p1受体调节剂及其晶体形式的方法 |
| US8822510B2 (en) | 2010-07-20 | 2014-09-02 | Bristol-Myers Squibb Company | Substituted 3-phenyl-1,2,4-Oxadiazole compounds |
| EP2619190B1 (en) | 2010-09-24 | 2015-08-12 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| EP2635573B1 (en) | 2010-11-03 | 2014-10-01 | Bristol-Myers Squibb Company | Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases |
| US9115054B2 (en) | 2013-02-21 | 2015-08-25 | Bristol-Myers Squibb Company | Tetrahydronaphthalenyl compounds useful as sipi agonists |
| ES2651367T3 (es) * | 2013-07-15 | 2018-01-25 | Basf Se | Compuestos plaguicidas |
| JP6413790B2 (ja) * | 2014-02-05 | 2018-10-31 | Jnc株式会社 | カルボニル誘導体、これらの化合物を含有する液晶組成物および液晶表示素子 |
| MA40082B1 (fr) | 2014-08-20 | 2019-09-30 | Bristol Myers Squibb Co | Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme |
| PL3242666T3 (pl) | 2015-01-06 | 2025-02-17 | Arena Pharmaceuticals, Inc. | Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1 |
| BR112017027656B1 (pt) | 2015-06-22 | 2023-12-05 | Arena Pharmaceuticals, Inc. | Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo |
| KR102482825B1 (ko) * | 2016-09-02 | 2022-12-29 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 트리시클릭 헤테로시클릭 화합물 |
| MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
| MX2019009843A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales. |
| US11046646B2 (en) | 2017-08-09 | 2021-06-29 | Bristol-Myers Squibb Company | Alkylphenyl compounds |
| US11059784B2 (en) | 2017-08-09 | 2021-07-13 | Bristol-Myers Squibb Company | Oxime ether compounds |
| CA3102136A1 (en) | 2018-06-06 | 2019-12-12 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the s1p1 receptor |
| CN112955431A (zh) | 2018-09-06 | 2021-06-11 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
| CN109411788B (zh) * | 2018-09-28 | 2021-07-13 | 北京化工大学 | 氮杂螺环阳离子负载型聚联苯碱性膜及其制备方法 |
| WO2024140968A1 (zh) * | 2022-12-30 | 2024-07-04 | 广州市联瑞制药有限公司 | 三环类化合物及其制备方法和应用 |
| CN120569392A (zh) * | 2022-12-30 | 2025-08-29 | 广州市联瑞制药有限公司 | 三环类化合物及其制备方法和应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL80628C (https=) * | 1949-07-23 | |||
| GB1354097A (en) | 1970-04-24 | 1974-06-05 | Teikoku Hormone Mfg Co Ltd | Isoxazole derivatives |
| GB1354098A (en) | 1970-04-24 | 1974-06-05 | Teikoku Hormone Mfg Co Ltd | 1-hydroxyiminonaphthalene derivatives |
| JPS4899161A (https=) | 1972-04-05 | 1973-12-15 | ||
| US3843666A (en) * | 1973-05-29 | 1974-10-22 | Sandoz Ag | Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles |
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| JPS6480026A (en) | 1987-09-21 | 1989-03-24 | Mitsubishi Electric Corp | Resist coater |
| EP0665840A1 (en) | 1992-10-23 | 1995-08-09 | MERCK SHARP & DOHME LTD. | Dopamine receptor subtype ligands |
| US6080745A (en) | 1993-09-15 | 2000-06-27 | Merck Sharp & Dohme Limited | Fused tricyclic heteroaromatic derivatives as dopamine receptor subtype ligands |
| US6069143A (en) | 1994-12-20 | 2000-05-30 | Smithkline Beecham Corporation | Fibrinogen receptor antagonists |
| AU710059B2 (en) | 1996-01-05 | 1999-09-09 | Aventis Pharmaceuticals Inc. | 4,5-dihydronaphth(1,2-C)isoxazoles and derivatives thereof having CNS activity |
| US5880121A (en) | 1996-01-05 | 1999-03-09 | Hoechst Marion Roussel Inc. | 4,5-dihydronaphth (1,2-c) isoxazoles and derivatives thereof |
| TW416953B (en) * | 1996-09-25 | 2001-01-01 | Takeda Chemical Industries Ltd | Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use |
| JP2001518501A (ja) * | 1997-10-06 | 2001-10-16 | ビーエーエスエフ アクチェンゲゼルシャフト | インデノ［１，２−ｃ］−、ナフト［１，２−ｃ］−およびベンゾ［６，７］シクロへプタ［１，２−ｃ］ピラゾール誘導体 |
| WO1999042455A1 (en) * | 1998-02-19 | 1999-08-26 | Tularik Inc. | Antiviral agents |
| EP1102755B1 (en) * | 1998-08-07 | 2006-01-04 | Chiron Corporation | Substituted isoxazole derivatives as estrogen receptor modulators |
| US6462036B1 (en) * | 1998-11-06 | 2002-10-08 | Basf Aktiengesellschaft | Tricyclic pyrazole derivatives |
| AU762992B2 (en) * | 1998-11-06 | 2003-07-10 | Abbott Gmbh & Co. Kg | Tricyclic pyrazole derivatives |
| DE19908538A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
| DE50014162D1 (de) | 1999-03-12 | 2007-04-26 | Basf Ag | Tricyclische benzoylpyrazol-derivate als herbizide |
| IL146481A0 (en) | 1999-06-01 | 2002-07-25 | Basf Ag | Tricyclic benzoylcyclohexanedione derivatives |
| ATE412638T1 (de) | 2001-02-16 | 2008-11-15 | Aventis Pharma Inc | Heterocyclische substituierte carbonyl derivate und ihre verwendung als dopamin d3 rezeptor liganden |
| EP1432706A2 (en) * | 2001-09-26 | 2004-06-30 | Bayer Pharmaceuticals Corporation | 3-pyridyl or 4-isoquinolinyl thiazoles as c17,20 lyase inhibitors |
| US20040267017A1 (en) * | 2001-09-26 | 2004-12-30 | Bierer Donald E | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors |
| AU2003207589B2 (en) * | 2002-01-16 | 2006-07-13 | University Of Virginia Patent Foundation | 2-Aminothiazole Allosteric Enhancers of A1 Adenosine Receptors |
| JP4430941B2 (ja) | 2002-01-18 | 2010-03-10 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体作動薬 |
| WO2003061567A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
| ATE448193T1 (de) | 2002-01-18 | 2009-11-15 | Merck & Co Inc | ßN-(BENZYL)AMINOALKYL CARBOXYLATE, PHOSPHINATE, PHOSPHONATE UND TETRAZOLE ALS EDG REZEPTORAGONISTENß |
| JP2005531506A (ja) | 2002-03-01 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体作動薬としてのアミノアルキルホスホネートおよび関連化合物 |
| ES2323952T3 (es) * | 2002-05-15 | 2009-07-28 | Janssen Pharmaceutica Nv | 3-aminopirazol triciclicos sustituidos en n como inhibidores receptores de pdfg. |
| JP2005533058A (ja) | 2002-06-17 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Ｅｄｇ受容体アゴニストとしての１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）アゼチジン−３−カルボキシラートおよび１−（（５−アリール−１，２，４−オキサジアゾール−３−イル）ベンジル）ピロリジン−３−カルボキシラート |
| WO2003105840A2 (en) | 2002-06-17 | 2003-12-24 | The Pennsylvania State Research Foundation | Sphingosine kinase inhibitors |
| JP2004018489A (ja) | 2002-06-19 | 2004-01-22 | Otsuka Pharmaceut Factory Inc | Ａｃａｔ−１阻害剤 |
| BRPI0407252A (pt) | 2003-02-07 | 2006-01-31 | Warner Lambert Co | Agentes antibacterianos. |
| US7320986B2 (en) * | 2003-03-07 | 2008-01-22 | Abbott Labortories | Fused tri and tetra-cyclic pyrazole kinase inhibitors |
| CL2004001120A1 (es) | 2003-05-19 | 2005-04-15 | Irm Llc | Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer. |
| EP1697333A4 (en) | 2003-12-17 | 2009-07-08 | Merck & Co Inc | (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR |
| EP1719771A1 (en) * | 2004-02-19 | 2006-11-08 | Takeda Pharmaceutical Company Limited | Pyrazoloquinolone derivative and use thereof |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| EP1740579B1 (en) * | 2004-03-24 | 2015-08-19 | AbbVie Inc. | Tricyclic pyrazole kinase inhibitors |
| CA2583681A1 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists |
| JP2008518957A (ja) | 2004-11-04 | 2008-06-05 | メルク エンド カムパニー インコーポレーテッド | ナイアシン受容体作動薬、そのような化合物を含んでいる組成物及び治療方法 |
| US7605269B2 (en) | 2005-03-23 | 2009-10-20 | Actelion Pharmaceuticals Ltd. | Thiophene derivatives as Sphingosine-1-phosphate-1 receptor agonists |
| WO2006115188A1 (ja) | 2005-04-22 | 2006-11-02 | Daiichi Sankyo Company, Limited | ヘテロ環化合物 |
| WO2006131336A1 (en) | 2005-06-08 | 2006-12-14 | Novartis Ag | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS |
| BRPI0615133A2 (pt) | 2005-08-23 | 2011-05-03 | Irm Llc | compostos imunossupressores, composições farmacêuticas contendo os mesmos assim como referido uso |
| AU2007227274A1 (en) | 2006-03-21 | 2007-09-27 | Epix Delaware, Inc. | S1P receptor modulating compounds |
| PL2003132T3 (pl) | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Pochodne oksadiazolu jako agoniści S1P1 |
| JP2009269819A (ja) | 2006-08-25 | 2009-11-19 | Asahi Kasei Pharma Kk | アミン化合物 |
| BRPI0719123A2 (pt) * | 2006-09-01 | 2013-12-17 | Cylene Pharmaceuticals Inc | Moduladores de serina-treonina proteína cinase e parp |
| PL2069335T3 (pl) | 2006-09-08 | 2013-05-31 | Actelion Pharmaceuticals Ltd | Pochodne pirydyn-3-ylu jako środki immunomodulujące |
| US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| WO2008051403A2 (en) * | 2006-10-20 | 2008-05-02 | Merck & Co., Inc. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| DK2089367T3 (da) * | 2006-10-31 | 2012-02-06 | Pfizer Prod Inc | Pyrazolinforbindelser som mineralocorticoidreceptor-antagonister |
| GB0625648D0 (en) | 2006-12-21 | 2007-01-31 | Glaxo Group Ltd | Compounds |
| WO2008094896A1 (en) * | 2007-01-31 | 2008-08-07 | Janssen Pharmaceutica, N.V. | N-substituted tricyclic 3-aminopyrazoles as anti-mitotic tubulin polymerization inhibitors |
| BRPI0808789A2 (pt) | 2007-03-16 | 2014-08-12 | Actelion Pharmaceuticals Ltd | Compostos e composição farmacêutica de derivados aminopiridina e uso destes |
| CL2008000793A1 (es) | 2007-03-23 | 2008-05-30 | Xenon Pharmaceuticals Inc | Compuestos derivados de dihidroindazol; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno del hierro. |
| MX2010003612A (es) | 2007-10-04 | 2010-04-30 | Merck Serono Sa | Derivados de oxadiazol. |
| KR20100092473A (ko) | 2007-11-01 | 2010-08-20 | 액테리온 파마슈티칼 리미티드 | 신규한 피리미딘 유도체 |
| EP2222668B1 (en) * | 2007-12-18 | 2011-11-02 | Arena Pharmaceuticals, Inc. | Tetrahydrocyclopenta[b]indol-3-yl carboxylic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| US20110052643A1 (en) | 2008-01-07 | 2011-03-03 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| MX2010010659A (es) * | 2008-03-31 | 2010-10-26 | Genentech Inc | Compuestos de benzopirano y benzoxepina, inhibidores de fosfoinoinositida 3-cinasas y metodos para utilizarlos. |
| CN104592231A (zh) | 2008-06-10 | 2015-05-06 | Abbvie公司 | 新的三环化合物 |
| US8580841B2 (en) | 2008-07-23 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders |
| IT1393930B1 (it) | 2009-02-25 | 2012-05-17 | Neuroscienze Pharmaness S C A R L | Composti farmaceutici |
-
2010
- 2010-10-29 US US13/504,541 patent/US9216972B2/en active Active
- 2010-10-29 EP EP13154679.8A patent/EP2592071B1/en not_active Not-in-force
- 2010-10-29 CN CN201080059932.3A patent/CN102686571B/zh not_active Expired - Fee Related
- 2010-10-29 KR KR1020127013598A patent/KR20130036171A/ko not_active Withdrawn
- 2010-10-29 AU AU2010319879A patent/AU2010319879A1/en not_active Abandoned
- 2010-10-29 WO PCT/US2010/054594 patent/WO2011059784A1/en not_active Ceased
- 2010-10-29 EP EP13154833.1A patent/EP2597089A1/en not_active Withdrawn
- 2010-10-29 JP JP2012537086A patent/JP5728487B2/ja not_active Expired - Fee Related
- 2010-10-29 MX MX2012004848A patent/MX336881B/es active IP Right Grant
- 2010-10-29 ES ES13154679T patent/ES2759949T3/es active Active
- 2010-10-29 EP EP10774099A patent/EP2493866A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013509431A5 (https=) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2019513778A5 (https=) | ||
| JP2014513110A5 (https=) | ||
| JP2011519854A5 (https=) | ||
| JP2010523522A5 (https=) | ||
| JP2015500307A5 (https=) | ||
| JP2019529484A5 (https=) | ||
| JP2019517487A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| JP2019512505A5 (https=) | ||
| JP2014514360A5 (https=) | ||
| JP2018519323A5 (https=) | ||
| RU2012112050A (ru) | Производные дигидроптеридинона, способ их получения и фармацевтическое применение | |
| RU2016134751A (ru) | Соединения | |
| JP2019524883A5 (https=) | ||
| JP2014037426A5 (https=) | ||
| JP2016520131A5 (https=) | ||
| JP2014503574A5 (https=) | ||
| JP2016530259A5 (https=) | ||
| JP2013512903A5 (https=) | ||
| JP2016509583A5 (https=) | ||
| JP2019522055A5 (https=) | ||
| JP2013537203A5 (https=) | ||
| JP2018507238A5 (https=) |